Oblimersen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Oblimersen
Accession Number
DB13811
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Synonyms
Not Available
Categories
UNII
85J5ZP6YSL
CAS number
190977-41-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Oblimersen.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Oblimersen.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Oblimersen.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Oblimersen.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oblimersen.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Oblimersen.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Oblimersen.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Oblimersen.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Oblimersen.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Oblimersen.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oblimersen.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oblimersen.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Oblimersen.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Oblimersen.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Oblimersen.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Oblimersen.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Oblimersen.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oblimersen.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Oblimersen.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Oblimersen.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Oblimersen.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Oblimersen
ATC Codes
L01XX36 — Oblimersen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedHealth Services ResearchMildly Impaired Renal Function / Moderately Impaired Renal Function / Normal Renal Function1
1CompletedTreatmentTumors, Solid1
1Unknown StatusTreatmentMelanoma1
2TerminatedTreatmentMelanoma1
2, 3TerminatedTreatmentAdvanced Melanoma and Normal or Impaired / Hepatic Function1
3CompletedTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:49 / Updated on July 02, 2018 19:56